Voyageur Pharmaceuticals Ltd
Company Overview
Voyageur Pharmaceuticals Ltd. is poised to become the only vertically integrated radiology drug manufacturer that controls its own critical mineral resources, including Barite and Iodine, in Canada and the USA. The company aims to be a major player in contrast media with a unique cost advantage by eliminating the need for external mineral suppliers, enabling 70%+ margins once fully operational and securing the North American supply chain.
Latest News
Voyageur Clarifies Terms of Previously Announced Agreement
Voyageur Pharmaceuticals Ltd. clarifies its distribution agreement for SmoothX 2%, stating it is not a sales contract as previously described. The agreement involves a USD $1.9 million commitment over three …
Analysis
No analysis found.
Frances Creek Quarry
The Frances Creek Asset is a unique geological anomaly, with pharmaceutical grade barite (Barium sulfate) resource. A Preliminary Economic Assessment (PEA) was submitted in 2022, showing an NPV of $344M …
Iodine Projects
Iodine will remain relevant due to its wider range of applications beyond Barium. FDA approval is in development, and the supply chain is also in development.
Executive Team
Filings data not yet available.
No Twitter handle configured for this company.